Latest Research And Development News

Imricor Medical Systems has achieved a major milestone with FDA clearance for its NorthStar Mapping System, the first MRI-native 3D cardiac mapping platform approved in the US. This approval positions Imricor at the forefront of MRI-guided cardiac procedures in the world’s largest electrophysiology market.

Omega Oil and Gas has secured a 19.43% stake in Elixir Energy, positioning itself for a major drilling push in Queensland’s Taroom Trough during 2026. Backed by a strong balance sheet, Omega aims to unlock significant gas and oil resources across multiple projects.

Adisyn Ltd has achieved a critical milestone in its pioneering low-temperature graphene deposition technology, validated by an independent expert, positioning the company for potential semiconductor industry integration.

Australian Silica Quartz Group advances metallurgical and high purity quartz projects with promising assay results, while progressing gold exploration at Koolyanobbing. The company strengthens its balance sheet following a rural property sale.

Elixir Energy has secured a $16.6 million capital injection led by Omega Oil and Gas, propelling its high-impact Lorelle-3 appraisal well drilling and expanding contingent gas resources in Queensland’s Taroom Trough.

Complii FinTech Solutions reported a solid 6.6% annual increase in recurring revenue and unveiled the first stage of a major CRM overhaul, signaling a strategic push to enhance its capital raising and compliance platform.

Australian Vanadium Limited has made significant strides in its integrated vanadium project, advancing its feasibility study and securing key environmental approvals while preparing to bid for a major Western Australian battery storage project.

Alliance Nickel reported a $769,000 placement and a $422,000 R&D tax refund while progressing its NiWest Nickel-Cobalt Project, despite renegotiating its Stellantis offtake agreement due to market shifts.

Radiopharm Theranostics has reported promising interim results from its Phase 2b trial of RAD 101, showing high concordance with MRI in brain metastases patients, while progressing multiple other clinical programs and securing a strong cash position to fund operations into 2027.

Bioxyne Limited has reported a record $17.2 million in quarterly revenue, driven by strong growth in its cannabis and psychedelics segments, alongside strategic international expansions including a Frankfurt dual listing and new manufacturing agreements.

Dubber Corporation Limited has signed a significant five-year contract with a major North American communications provider, while trimming costs and targeting operating cashflow breakeven in FY26.

LTR Pharma has marked a key milestone with over 1,000 SPONTAN prescriptions under Australia’s Special Access Scheme and is advancing clinical trials and US market preparations for its erectile dysfunction treatments.